Evidence map›Paper›PMID 41109900›Full record

ArticleBone marrow transplantation2026

Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT.

Arnon Nagler, Jacques-Emmanuel Galimard, Sarah Kayser, Alexander Kulagin, Didier Blaise, Elena Parovichnikova, Jurjen Versluis, Maija Itäla-Remes, Goda Choi, Rodrigo Martino Bufarull and 7 more

Abstract readMulticenter Study
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Arnon NaglerDivision of Hematology, Sheba Medical Center, Tel Hashomer, Israel. arnon.nagler@sheba.health.gov.il.ORCID 0000-0002-0763-1265
Jacques-Emmanuel GalimardEBMT Paris Study Unit; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.ORCID 0000-0001-9102-4427
Sarah KayserDepartment of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-9985-1205
Alexander KulaginRM Gorbacheva Research Institute, Pavlov University, Petersburg, Russian Federation.ORCID 0000-0002-9589-4136
Didier BlaiseProgramme de Transplantation &Thérapie Cellulaire, Marseille, France.ORCID 0000-0002-5684-9447
Elena ParovichnikovaNational Research Center for Hematology, Moscow, Russian Federation.
Jurjen VersluisErasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0003-2372-1663
Maija Itäla-RemesTurku University Hospital, Turku, Finland.
Goda ChoiUniversity Medical Center Groningen (UMCG), Groningen, The Netherlands.
Rodrigo Martino BufarullHospital Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0001-5143-4042
Simona SicaUniversita Cattolica S. Cuore, Rome, Italy.ORCID 0000-0003-2426-3465
Mieke W H RoevenRadboud University Medical center, Nijmegen, The Netherlands.
Peter von dem BorneLeiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7470-7346
Ali BazarbachiHematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.ORCID 0000-0002-7171-4997
Jaime SanzHematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain.ORCID 0000-0001-6934-4619
Mohamad MohtyEBMT Paris Study Unit; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.ORCID 0000-0002-7264-808X
Fabio CiceriOspedale San Raffaele, Haematology and BMT, Milano, Italy.ORCID 0000-0003-0873-0123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed pGF in 2497 AML patients undergoing HSCT from 8-10/10 HLA-matched UD with PTCy. pGF was defined as failure to achieve an ANC ≥ 0.5 × 10

Indexed as

CyclophosphamideHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteTransplantation ConditioningAdolescentAdultAgedFemaleHumansMaleMiddle AgedUnrelated DonorsYoung AdultCyclophosphamide

Identifiers

PMID41109900
PMCPMC12819139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.